# Data Sheet (Cat.No.T34286)

TargetMol
YOUR TARGET MOLECULES

## Remogliflozin etabonate

### Chemical Properties



CAS No. : 442201-24-3

Formula: C26H38N2O9

Molecular Weight: 522.59

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

### Biological Description

| | |
|---|---|
| Description | Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively. |
| Targets(IC50) | SGLT |
| In vivo | Oral administration of Remogliflozin etabonate (10-30 mg/kg) dose-dependently reduces the levels of FPG and GHb. Oral administration of Remogliflozin etabonate (3-30 mg/kg) dose-dependently increases urine volume and urinary glucose excretion[2]. |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 90.0 mg/mL (172.2 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.9135 mL | 9.5677 mL | 19.1355 mL |
| 5 mM | 0.3827 mL | 1.9135 mL | 3.8271 mL |
| 10 mM | 0.1914 mL | 0.9568 mL | 1.9135 mL |
| 50 mM | 0.0383 mL | 0.1914 mL | 0.3827 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Nakano S, et al. Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. J Clin Exp Hepatol. 2015 Sep;5(3):190-8.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481